Pedro At
25/04/16 17:34
Ha respondido al tema
Farmas USA
SRPT
Hoy tiene comite, esperando noticias !! se esperan positivas.. pero ya conocemos como actua FDA .(
As expected, Nasdaq halts trading in Sarepta Therapeutics (NASDAQ:SRPT) pending news of the outcome of today's Ad Comm review of eteplirsen for the treatment of Duchenne muscular dystrophy DMD amenable to skipping exon 51.It should be a lively affair since many DMD activists will be attending the meeting in order to pressure the committee to vote for approval despite the absence of definitive data proving efficacy
y para el 26 de mayo PDUFA (PDUFA goal date extended by standard extension period of three months to May 26, 2016)
ya veremos como salgo de esta..